-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Adaptive Biotechnologies, Lowers Price Target to $19

Benzinga·05/06/2026 20:16:47
Listen to the news
JP Morgan analyst Sebastian Sandler maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and lowers the price target from $21 to $19.